Market Research International

Global Opioid-Induced Constipation Market 2015-2019

Press Release   •   Aug 10, 2015 02:53 EDT

About Opioid-induced Constipation
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.
The report's analysts forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.
On the basis of the mechanism of action of drugs, the market is grouped into the following categories:
- Peripherally Acting Mu-opioid Receptor Antagonist
- Locally Acting Chloride Channel Activator
- Others
On the basis of the route of administration of drugs, the market is grouped into the following categories:
- Oral
- Parenteral
On the basis of the dosage form of drugs, the market is grouped into the following categories:
- Solid
- Liquid
This market report, Global Opioid-induced Constipation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
- Americas
Key Vendors
- AstraZeneca
- Takeda Pharmaceutical
- Valeant Pharmaceuticals International
Other Prominent Vendors

- Abbott
- Bayer
- Boehringer Ingelheim
- C.B. Fleet
- Cosmo Pharmaceuticals
- Daewoong
- Daiichi Sankyo
- GlaxoSmithKline
- Ironwood Pharmaceuticals
- Johnson & Johnson
- Merck
- Mundipharma
- Nektar Therapeutics
- Pfizer
- Progenics Pharmaceuticals
- Shionogi
- SLA Pharma
- Sucampo
- Synergy Pharmaceuticals
- Theravance
Market Driver
- Unmet Medical Needs
- For a full, detailed list, view our report
Market Challenge
- Availability of OTC and Off-label Drugs
- For a full, detailed list, view our report
Market Trend
- Shift to Targeted Therapy
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Market Research International is a leading distributor of PREMIUM market research reports.